Section Arrow
ACRS.NASDAQ
- Aclaris Therapeutics
Quotes are at least 15-min delayed:2026/11/04 13:17 EST
Regular Hours
Last
 3.735
-0.005 (-0.13%)
Day High 
3.88 
Prev. Close
3.74 
1-M High
4.41 
Volume 
821.37K 
Bid
3.73
Ask
3.74
Day Low
3.645 
Open
3.81 
1-M Low
3.1818 
Market Cap 
579.64M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.84 
20-SMA 3.7 
50-SMA 4.78 
52-W High 6.5999 
52-W Low 2.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.58/-0.62
Enterprise Value
590.30M
Balance Sheet
Book Value Per Share
0.80
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.83M
Operating Revenue Per Share
0.14
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.2499+0.536+75.08%0.2PE
KPTIKaryopharm Therapeutics Inc.0.09+0.0017+1.93%-- 
GERNGeron Corp1.035+0.105+11.29%-- 
INOInovio Pharmaceuticals1.73+0.07+4.22%-- 
RXRXRecursion Pharmaceuticals3.89+0.21+5.71%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.